{
    "clinical_study": {
        "@rank": "100742", 
        "arm_group": [
            {
                "arm_group_label": "Active vs Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "In phase I, subjects will be randomized into either the VSL#3 probiotics or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotics (2 sachets/ day or 900 billion bacteria/day) or placebo (2 placebo sachets/day) for the first 60 days."
            }, 
            {
                "arm_group_label": "60 days of Active vs 120 days of Active", 
                "arm_group_type": "Active Comparator", 
                "description": "In phase II, subjects from both arms in phase I will receive VSL#3 probiotics 2 sachets/ day for another 60 days. Comparison will be made between the arm receiving 60 days of VSL#3 probiotics vs 120 days of VSL#3 probiotics"
            }
        ], 
        "brief_summary": {
            "textblock": "SSc-associated gastrointestinal (GI) involvement is common, with no effective treatment.\n      Probiotics may have beneficial effects on symptoms as supported by one small open-label\n      study (n=10) that demonstrated decreased bloating symptoms in SSc patients after 2 months of\n      probiotics. This study aims to determine (i)  whether 60 days of VSL#3 probiotics result in\n      greater GI symptom improvement than placebo in SSc outpatients, assessed using an\n      interview-administered 34-item Gastrointestinal Tract (GIT) questionnaire and (ii) whether\n      60 days versus 120 days of probiotics result in greater GI symptom improvement in SSc\n      outpatients, assessed using the GIT questionnaire."
        }, 
        "brief_title": "Clinical Trial of Probiotics in Systemic Sclerosis Associated Gastrointestinal Disease", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Systemic Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Gastrointestinal Diseases", 
                "Digestive System Diseases", 
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  SSc that fulfills the American College of Rheumatology (ACR, 1990) classification\n             criteria or the proposed European League Against Rheumatism (EULAR) criteria for very\n             early diagnosis of systemic sclerosis.\n\n          -  SSc overlap syndromes (ie SSc occurring in overlap with other connective tissue\n             diseases)\n\n          -  SSc-associated GI symptoms (heartburn, dysphagia, vomiting, bloating/distension,\n             faecal soilage, diarrhoea, constipation) not due to other causes as determined by\n             clinical evaluation, with a total GIT score of at least 0.10\n\n          -  Stable doses of immunosuppressive treatment, corticosteroids, and GI medications for\n             30 days.\n\n        Exclusion Criteria:\n\n          -  On anti-biotics or probiotics within the last 30 days\n\n          -  Current serious infections requiring hospitalization\n\n          -  Long-term indwelling catheter, including patients on total parenteral nutrition\n\n          -  Females who are lactating or pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804959", 
            "org_study_id": "AL-SScGI"
        }, 
        "intervention": {
            "arm_group_label": [
                "Active vs Placebo", 
                "60 days of Active vs 120 days of Active"
            ], 
            "intervention_name": "VSL#3 probiotics", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 3, 2013", 
        "location": {
            "contact": {
                "email": "andrea.low.h.l@sgh.com.sg", 
                "last_name": "Dr Low Hsiu Ling Andrea", 
                "phone": "63214028"
            }, 
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore", 
                    "zip": "169608"
                }, 
                "name": "Singapore General Hospital"
            }, 
            "investigator": {
                "last_name": "Low Hsiu Ling Andrea", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Proof-of-concept Double-blind Randomized Placebo-controlled Trial of Probiotics in Systemic Sclerosis Associated Gastrointestinal Disease", 
        "overall_contact": {
            "email": "andrea.low.h.l@sgh.com.sg", 
            "last_name": "Dr Low Hsiu Ling Andrea", 
            "phone": "63214028"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Singapore: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "mean difference between probiotics group versus placebo group in gastrointestinal change score from baseline to day 60 of treatment.", 
            "safety_issue": "No", 
            "time_frame": "After 60 days of either placebo treatment or active drug treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804959"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "mean difference between 60 days of probiotics versus 120 days of probiotics in gastrointestinal change score from baseline to day 120 of treatment.", 
            "safety_issue": "No", 
            "time_frame": "After 120 days of placebo treatment or active drug treatment"
        }, 
        "source": "Singapore General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Singapore General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}